Tosedostat, a novel Anti-Tumour drug

TOSEDOSTAT is an oral aminopeptidase inhibitor that has demonstrated anti -tumour response in blood cancers and solid tumours  in phase 1-2 clinical trials .At present, phase 2/3 is being conducted referred to as AML less intensive(LI-D trial).
         Aminopeptidases are required by tumour cells to provide amino acids necessary for growth and survival .
                Tosedostat is curently being evaluated in multiple phase 2 trials for treatment of patients with Acute Myeloid Leukemia(AML) or high risk Myelodysplastic Syndrome(MDS)

CTI BIOPHARMA, acquires world wide rights to Tosedostat

CTI Biopharma has acquired world wide rights to TOSEDOSTAT through concurrent transactions with Vernalis R&D Ltd and Chroma Therapeutics.Under terms of assets purchase agreement with Chroma Therapeutics , CTI Biopharma acquired Chroma rights,titlle , and interest in TOSEDOSTAT  in exchng for USD 21.3 million in shares to  Chroma Therapeutics.Also CTI Biopharma entered in to license agreement with Vernalis R&D for world wide rights to use IPR(intellectual property rights) and certain patents to develop , market and commercialize TOSEDOSTAT.